T. Kouzarides, Chromatin Modifications and Their Function, Cell, vol.128, issue.4, pp.693-705, 2007.
DOI : 10.1016/j.cell.2007.02.005

URL : http://doi.org/10.1016/j.cell.2007.02.005

G. G. Wang, C. D. Allis, and P. Chi, Chromatin remodeling and cancer, part I: covalent histone modifications, Trends in Molecular Medicine, vol.13, issue.9, pp.13-363, 2007.
DOI : 10.1016/j.molmed.2007.07.003

P. Chi, C. D. Allis, and G. G. Wang, Covalent histone modifications ??? miswritten, misinterpreted and mis-erased in human cancers, Nature Reviews Cancer, vol.21, issue.7, pp.457-469, 2010.
DOI : 10.1038/nrc2876

A. Mai and L. Altucci, Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead, The International Journal of Biochemistry & Cell Biology, vol.41, issue.1, p.41, 2009.
DOI : 10.1016/j.biocel.2008.08.020

M. Albert and K. Helin, Histone methyltransferases in cancer, Seminars in Cell & Developmental Biology, vol.21, issue.2, pp.209-220, 2010.
DOI : 10.1016/j.semcdb.2009.10.007

A. Mai, Small-molecule chromatin-modifying agents: therapeutic applications, Epigenomics, vol.2, issue.2, pp.307-324, 2010.
DOI : 10.2217/epi.10.7

D. Rotili and A. Mai, Targeting Histone Demethylases: A New Avenue for the Fight against Cancer, Genes & Cancer, vol.2, issue.6, pp.663-679, 2011.
DOI : 10.1177/1947601911417976

D. Cheng, N. Yadav, R. W. King, M. S. Swanson, E. J. Weinstein et al., Small Molecule Regulators of Protein Arginine Methyltransferases, Journal of Biological Chemistry, vol.279, issue.23, pp.279-23892, 2004.
DOI : 10.1074/jbc.M401853200

R. Ragno, S. Simeoni, S. Castellano, C. Vicidomini, A. Mai et al., Small Molecule Inhibitors of Histone Arginine Methyltransferases:?? Homology Modeling, Molecular Docking, Binding Mode Analysis, and Biological Evaluations, Journal of Medicinal Chemistry, vol.50, issue.6, pp.50-1241, 2007.
DOI : 10.1021/jm061213n

S. Castellano, C. Milite, R. Ragno, S. Simeoni, A. Mai et al., Design, Synthesis and Biological Evaluation of Carboxy Analogues of Arginine Methyltransferase Inhibitor???1 (AMI-1), ChemMedChem, vol.25, issue.3, pp.398-414, 2010.
DOI : 10.1002/cmdc.200900459

A. Mai, S. Valente, D. Cheng, A. Perrone, R. Ragno et al., Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors, ChemMedChem, vol.421, issue.7, pp.987-991, 2007.
DOI : 10.1002/cmdc.200700023

R. Costi, R. D. Santo, M. Artico, G. Miele, P. Valentini et al., Cinnamoyl Compounds as Simple Molecules that Inhibit p300 Histone Acetyltransferase, Journal of Medicinal Chemistry, vol.50, issue.8, p.50, 2007.
DOI : 10.1021/jm060943s

A. Mai, D. Cheng, M. T. Bedford, S. Valente, A. Nebbioso et al., Epigenetic Multiple Ligands: Mixed Histone/Protein Methyltransferase, Acetyltransferase, and Class III Deacetylase (Sirtuin) Inhibitors, Journal of Medicinal Chemistry, vol.51, issue.7, pp.51-2279, 2008.
DOI : 10.1021/jm701595q

D. Cheng, S. Valente, S. Castellano, G. Sbardella, R. D. Santo et al., Novel 3,5-Bis(bromohydroxybenzylidene)piperidin-4-ones as Coactivator-Associated Arginine Methyltransferase 1 Inhibitors: Enzyme Selectivity and Cellular Activity, Journal of Medicinal Chemistry, vol.54, issue.13, pp.5-54, 2011.
DOI : 10.1021/jm200453n

URL : https://hal.archives-ouvertes.fr/pasteur-00968654

K. Nishioka, J. C. Rice, K. Sarma, H. Erdjument-bromage, J. Werner et al., PR-Set7 Is a Nucleosome-Specific Methyltransferase that Modifies Lysine 20 of Histone H4 and Is Associated with Silent Chromatin, Molecular Cell, vol.9, issue.6, pp.1201-1213, 2002.
DOI : 10.1016/S1097-2765(02)00548-8

S. Wu and J. C. Rice, A new regulator of the cell cycle, Cell Cycle, vol.283, issue.1, pp.68-72, 2011.
DOI : 10.1016/j.molcel.2007.07.012

D. Patnaik, H. G. Chin, P. O. Esteve, J. Benner, S. E. Jacobsen et al., Substrate Specificity and Kinetic Mechanism of Mammalian G9a Histone H3 Methyltransferase, Journal of Biological Chemistry, vol.279, issue.51, pp.279-53248, 2004.
DOI : 10.1074/jbc.M409604200

M. W. Chen, K. T. Hua, H. J. Kao, C. C. Chi, L. H. Wei et al., H3K9 Histone Methyltransferase G9a Promotes Lung Cancer Invasion and Metastasis by Silencing the Cell Adhesion Molecule Ep-CAM, H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM, pp.7830-7840, 2010.
DOI : 10.1158/0008-5472.CAN-10-0833

K. Nishioka, S. Chuikov, K. Sarma, H. Erdjument-bromage, C. D. Allis et al., Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation, Genes Dev. J. Biol. Chem, vol.16, issue.283, pp.26771-26781, 2002.

L. E. Surface, S. R. Thornton, and L. A. Boyer, Polycomb Group Proteins Set the Stage for Early Lineage Commitment, Cell Stem Cell, vol.7, issue.3, pp.288-298, 2010.
DOI : 10.1016/j.stem.2010.08.004

M. Sauvageau and G. Sauvageau, Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer, Cell Stem Cell, vol.7, issue.3, pp.299-313, 2010.
DOI : 10.1016/j.stem.2010.08.002

D. P. Tsang and A. S. Cheng, Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2, Journal of Gastroenterology and Hepatology, vol.112, issue.1, p.26, 2011.
DOI : 10.1111/j.1440-1746.2010.06447.x

C. G. Kleer, Q. Cao, S. Varambally, R. Shen, I. Ota et al., EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells, Proc. Natl. Acad. Sci. U.S.A, p.100, 2003.
DOI : 10.1073/pnas.1933744100

S. Varambally, S. M. Dhanasekaran, M. Zhou, T. R. Barrette, C. Kumar-sinha et al., The polycomb group protein EZH2 is involved in progression of prostate cancer, Nature, vol.159, issue.6907, pp.624-629, 2002.
DOI : 10.1074/jbc.M107795200

J. Yu, D. R. Rhodes, S. A. Tomlins, X. Cao, G. Chen et al., A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome, Cancer Research, vol.67, issue.22, 2007.
DOI : 10.1158/0008-5472.CAN-07-2498

G. H. Richter, S. Plehm, A. Fasan, S. Rossler, R. Unland et al., EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation, Proc. Natl. Acad. Sci. U.S.A. 106, pp.5324-5329, 2009.
DOI : 10.1073/pnas.0810759106

J. Lee, M. J. Son, K. Woolard, N. M. Donin, A. Li et al., Epigenetic-Mediated Dysfunction of the Bone Morphogenetic Protein Pathway Inhibits Differentiation of Glioblastoma-Initiating Cells, Cancer Cell, vol.13, issue.1, pp.69-80, 2008.
DOI : 10.1016/j.ccr.2007.12.005

C. Wang, Z. Liu, C. W. Woo, Z. Li, L. Wang et al., EZH2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes CASZ1, CLU, RUNX3, and NGFR, EZH2 mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3 and NGFR, pp.315-324, 2012.
DOI : 10.1158/0008-5472.CAN-11-0961